Mergers & acquisitions
Creat Group will attempt to restructure its $1.5M offer to acquire Biotest after U.S. regulators nixed the deal.
The PE firm made the investment just three years ago.
A little more than two years after acquiring Sprout, Valeant is selling off the developer of the female sex drive drug Addyi.
Tonghua Golden-Horse Pharma and Golden Meditech Holdings -- will submit bids in the second round of an auction to acquire I-MED Radiology.
The acquisition is expected to close by the end of 2017.
Neurocrine’s third-quarter financial results didn’t just impress, they blew everybody away.
Mallinckrodt has agreed to buy Ocera Therapeutics in a deal that could hit $117M.
Days after plunking down $3.9B+ for AAA, Novartis may be looking to divest itself of its generic dermatology drug business.
Allergan released its third-quarter financials, with mixed results and plans to make fairly major changes.
Shares of Halyard Health are up more than 12 percent after the company announced it was selling its S&IP business to Owens & Minor for $710M.
PRESS RELEASES